Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
Latest Information Update: 31 Jul 2023
Price :
$35 *
At a glance
- Drugs Degarelix (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 25 Jul 2023 Status changed from active, no longer recruiting to completed.
- 29 May 2021 New trial record